| Literature DB >> 22326217 |
Martin G Myers1, Steven B Heymsfield, Carol Haft, Barbara B Kahn, Maren Laughlin, Rudolph L Leibel, Matthias H Tschöp, Jack A Yanovski.
Abstract
The widespread use of the inadequately defined term "leptin resistance" led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22326217 PMCID： PMC3281561 DOI： 10.1016/j.cmet.2012.01.002
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287